HALOHalozyme Therapeutics, Inc.

HALO Stock Price, Valuation & Chart | Halozyme Therapeutics, Inc.

Compare

$107.72+1.23 (+1.16%)

At close · 01 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology HALO intrinsic value HALO calculated fair value vs price

Overview Financials Dividends Ratios

HALO Historical price chart

HALO Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization12.78B

PE Ratio20.1

EPS5.36

Trading Volume1.06M

Today's High/Low108.53/106.9

Dividend Yield0.00

52 Week High/Low109.66/61.23

Shares Outstanding118.61M

HALO Financial Statement

HALO Analyst ratings

HALO Analysis & performance metrics

HALO Company profile

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's…

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies…

HALO Management team

Name

Position

Helen I. Torley M.B. Ch. B., M.R.C.P.CEO

President, Chief Executive Officer & Director

Tram Bui

Head of Investor Relations & Corporate Communications

Christopher Wahl M.B.A., M.D.

Chief Business Officer

Nicole LaBrosse CPACFO

Senior Vice President & Chief Financial Officer

Charles P. Theuer M.D., Ph.D.

Chief Medical Officer

Cortney Caudill M.B.A.

Chief Operations Officer

Gary Grote

Chief Commercial Officer

Mark Snyder Esq.

Senior Vice President, General Counsel, Chief Compliance Officer & nd Secretary

Name

Position

Helen I. Torley M.B. Ch. B., M.R.C.P.CEO

President, Chief Executive Officer & Director

Tram Bui

Head of Investor Relations & Corporate Communications

Christopher Wahl M.B.A., M.D.

Chief Business Officer

Nicole LaBrosse CPACFO

Senior Vice President & Chief Financial Officer

Charles P. Theuer M.D., Ph.D.

Chief Medical Officer

Cortney Caudill M.B.A.

Chief Operations Officer

Gary Grote

Chief Commercial Officer

Mark Snyder Esq.

Senior Vice President, General Counsel, Chief Compliance Officer & nd Secretary

Management Team

Helen I. Torley M.B. Ch. B., M.R.C.P.CEO

President, Chief Executive Officer & Director

Tram Bui

Head of Investor Relations & Corporate Communications

Christopher Wahl M.B.A., M.D.

Chief Business Officer

Nicole LaBrosse CPACFO

Senior Vice President & Chief Financial Officer

Charles P. Theuer M.D., Ph.D.

Chief Medical Officer

Cortney Caudill M.B.A.

Chief Operations Officer

Gary Grote

Chief Commercial Officer

Mark Snyder Esq.

Senior Vice President, General Counsel, Chief Compliance Officer & nd Secretary

Management

Helen I. Torley M.B. Ch. B., M.R.C.P.CEO

President, Chief Executive Officer & Director

Tram Bui

Head of Investor Relations & Corporate Communications

Christopher Wahl M.B.A., M.D.

Chief Business Officer

Nicole LaBrosse CPACFO

Senior Vice President & Chief Financial Officer

Charles P. Theuer M.D., Ph.D.

Chief Medical Officer

Cortney Caudill M.B.A.

Chief Operations Officer

Gary Grote

Chief Commercial Officer

Mark Snyder Esq.

Senior Vice President, General Counsel, Chief Compliance Officer & nd Secretary

Total 8 executives

HALO Frequently asked questions

What is Halozyme Therapeutics, Inc. (HALO) Stock Price?

Current stock price of Halozyme Therapeutics, Inc. (HALO) stock is $107.72. The stock price is +1.16% higher in the session. The intraday range can be seen from this page. Volume of Halozyme Therapeutics, Inc. (HALO) stock is 1.06M.

Last updated at 01 Sept 2026, 08:00 pm.

Why is the Halozyme Therapeutics, Inc. (HALO) stock price going up or down today?

The stock price of Halozyme Therapeutics, Inc. (HALO) can change with earnings, company news, and overall market sentiment. Halozyme Therapeutics, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Halozyme Therapeutics, Inc. stock expensive at its current price?

Whether Halozyme Therapeutics, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for HALO on this page is 20.10. EPS on this page is 5.36. Compare those figures with peers and growth expectations before deciding if the current Halozyme Therapeutics, Inc. price is justified.

How has the stock price of Halozyme Therapeutics, Inc. (HALO) performed historically?

Historical performance for Halozyme Therapeutics, Inc. (HALO) is shown on the price chart on this page. Review multi-period moves alongside volume to see how HALO reacted to past earnings and market events.

Should I buy Halozyme Therapeutics, Inc. (HALO) stock, at this price?

Buying Halozyme Therapeutics, Inc. (HALO) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.